Palo Alto Investors »

Celldex Therapeutics shares owned by Palo Alto Investors

Quarter-by-quarter ownership of Celldex Therapeutics (CLDX) shares owned by Palo Alto Investors from 13F filings

Historical chart of Palo Alto Investors investment in Celldex Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Celldex Therapeutics held by Palo Alto Investors consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Celldex Therapeutics by Palo Alto Investors

Quarter filed Position value Share count Share price at filing
2026-03-31 $9.4M 296k 31.72

More positions owned by Palo Alto Investors

Insmed Com Par $.01 (INSM)
ACADIA Pharmaceuticals (ACAD)
Ptc Therapeutics I (PTCT)
BioMarin Pharmaceutical (BMRN)
United Therapeutics Corporation (UTHR)
Anaptysbio Inc Common (ANAB)
Mirum Pharmaceuticals (MIRM)
Dyne Therapeutics (DYN)
Biogen Idec (BIIB)
Disc Medicine (IRON)
Iovance Biotherapeutics (IOVA)
Syndax Pharmaceuticals (SNDX)
Annexon (ANNX)
Amicus Therapeutics (FOLD)
Novocure Ord Shs (NVCR)

View all positions for Palo Alto Investors

Top funds holding Celldex Therapeutics

Wellington Management Company
Kynam Capital Management
BlackRock
Vanguard Group
FMR
Point72 Asset Management
Vanguard Capital Management
State Street Corporation
Commodore Capital
Eversept Partners
Geode Capital Management
Braidwell
Deep Track Capital
Millennium Management
Vestal Point Capital

View all funds holding Celldex Therapeutics